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Abstract
Background: Toxoplasma gondii is an opportunistic protozoan closely associated with AIDS and vertical transmission.
T. gondii actin depolymerizing factor (TgADF) plays an important role in actin cytoskeleton remodeling, and it is
required to invade host cells. TgADF was a promising vaccine candidate. To observe the immunological changes and
protective efficacy of recombinant TgADF protein (rTgADF) against T. gondii infection, we optimized the intranasal
immunization dose of rTgADF and analyzed the survival rate and tachyzoite loads in mouse tissues after oral challenge
with T. gondii tachyzoites.
Results: rTgADF was prepared, purified, and combined with mouse anti-His antibody and rabbit anti-T. gondii serum.
After intranasal immunization with 10 μg, 20 μg, 30 μg, or 40 μg of rTgADF, the 30-μg group elicited high levels of
secretory IgA (sIgA) in nasal, intestinal, and vesical washes, raised IgG titres in the sera, strong proliferation of
splenocytes, and increased secretion of IL-2 and IFN-γ when compared with the control group. When the mice
were orally challenged with T. gondii, an increase in the survival rate (36.36 %) and a decrease in the tachyzoite
loads in the liver (67.77 %) and brain (51.01 %) were observed.
Conclusions: Our findings demonstrate that intranasal immunization with rTgADF can simultaneously trigger
mucosal and systemic immune responses and protect the mice against T. gondii infection.
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Background
Toxoplasma gondii is an obligate intracellular protozoan
that invades the nucleated cells of humans and many
other mammals. T. gondii is the causative agent of toxo-
plasmosis. About one-third of world’s population has been
infected by T. gondii [1]. Healthy individuals are usually
asymptomatic; however, patients with AIDS or other im-
munosuppressive diseases may exhibit encephalitis and
blindness or even die [2]. In pregnant women, toxoplas-
mosis can lead to abortion, stillbirth, fetal abnormalities,
and congenital toxoplasmosis [3]. In addition, toxoplas-
mosis in domestic animals can result in substantial eco-
nomic losses to the farming industry and threaten the
health of humans who eat undercooked meat [4]. Cur-
rently, no specific medicine is available to prevent and
cure the disease. Therefore, an effective vaccine against T.
gondii infection is required [5].
The first commercial vaccine for toxoplasmosis was
used to control abortion in sheep [6]. However, this vac-
cine from the live-attenuated S48 strain was not appro-
priate for humans because it could revert to the
pathogenic strain [7]. Subsequently, many studies fo-
cused on crude inactivated antigen vaccines, subunit
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vaccines, and DNA vaccines, but there is no currently avail-
able vaccine to prevent T. gondii infection in humans [8, 9].
Further studies are required to screen for efficacious target
antigens and deliver them to produce appropriate protect-
ive immunity via an optimal administration strategy [5].
T. gondii depends on gliding motility to invade host
cells, and it needs power obtained from actin filament
polymerization and turn-over [10]. T. gondii actin de-
polymerizing factor (TgADF) promotes efficient turn-
over of actin filaments via weak severing of filaments
and strong sequestering of monomers [11, 12]. As early
as 1997, TgADF had been identified, and recombinant
TgADF (rTgADF) could bind actin monomers and
depolymerize F-actin [13]. BALB/c mice vaccinated with
pVAX1-TgADF or rTgADF displayed specific humoral
and cellular immune responses, prolonged survival time,
and reduced brain cyst load [14, 15]. Therefore, TgADF
is a promising vaccine candidate.
Previous studies have shown that the survival time of
mice intramuscularly immunized with pVAX1-TgADF or
rTgADF was longer than that of the control groups, but
it was not statistically significant [14, 15]. In addition,
the mice were challenged intraperitoneally with tachy-
zoites of T. gondii, which did not conform to the natural
infection route. We needed to optimize the experimental
conditions to improve the protective efficacy of the
vaccine.
T. gondii infection is caused by the ingestion of an oo-
cyst, cyst, or pseudocyst. The intestinal mucosal barrier
provides the initial defense to prevent the infection. It is
logical to pursue a vaccination approach that elicits a
potent defense at the invasion site and maintains long-
lasting protective immunity [16]. As a result, the nasal
route is suitable for eliciting mucosal and systemic im-
mune responses [17]. A previous study has shown that
intranasal administration of CpG/TLA could provide a
stable, pronounced, and effective vaccine against toxoplas-
mosis when compared with intramuscular administration
[18]. In the present study, we prepared rTgADF, deter-
mined the optimal dose for intranasal immunization, and
evaluated the protective efficacy against T. gondii infection
in BALB/c mice.
Methods
Mice and T. gondii strain
Specific-pathogen-free female BALB/c mice (4–6 weeks
of age) were purchased from the Chinese Academy of
Medical Science Animal Center (Beijing, China). All
mice were bred with food and water provided ad libi-
tum. Tachyzoites of the T. gondii RH strain were stored
in liquid nitrogen in the laboratory and maintained by
intraperitoneal passaging in BALB/c mice, as described
previously [19]. This study was conducted according to
the Guidelines for the Laboratory Animal Use and Care
Committee of the Ministry of Health, China and the
Ethics Committee on Animal Research of Xuzhou Med-
ical University (No. SCXK < SU > 2014–0003).
Construction of the recombinant plasmid
Total RNA of T. gondii tachyzoites was extracted using
the TRIzol reagent (life,CA, USA). The complete open
reading frame (ORF) of TgADF (GenBank: U62146.1)
was amplified using polymerase chain reaction (PCR)
from the cDNA template with specific primers (forward
primer: 5′-ACGCGGATCCATGGCGTCCGGAATGG
GTG-3′ and reverse primer: 5′-ACCGCTCGAGCGCG
AGGGGTGCGAGGTC-3′), in which BamHI and XhoI
were introduced (underlined). The following PCR con-
ditions were used: 94 °C for 3 min, followed by 30 cycles
of 94 °C for 30 s, 56 °C for 30 s, and 72 °C for 30 s and
72 °C for 7 min. The PCR products were cloned into
the prokaryotic expression vector pET30a(+) to obtain
pET-30a(+)-TgADF used to transform Escherichia coli
DH5α competent cells. The positive plasmids were con-
firmed using restriction enzyme digestion, PCR, and
DNA sequencing.
Preparation of the recombinant protein
E. coli BL21/DE3 transformed with pET-30a(+)-TgADF
were grown in Luria-Bertani (LB) medium supplemented
kanamycin (50 μg/mL) at 37 °C until an optical density
(OD600) of 0.4–0.6 was achieved. The expression was in-
duced by adding 0.1 mM isopropyl-β-D-thiogalactopy-
ranoside (IPTG) and maintaining the medium at 25 °C
for 12 h. The bacterial pellets were harvested and lysed
by sonication in an iced water bath for 15 min (power,
200 W; pulse on, 5 s; pulse off, 15 s). To prevent pro-
tein degradation, all subsequent steps were performed
at 4 °C. After centrifugation at 8,000 × g for 15 min, the
supernatant was mixed with Ni-NTA agarose (Qiagen,
Germany) for 1 h. The column was washed with a buf-
fer containing 20 mM imidazole, 50 mM NaH2PO4,
and 300 mM NaCl. The target protein was eluted by in-
creasing the imidazole concentration to 150 mM. The
endotoxin was removed and detected using the Toxi-
nEraser™ Endotoxin Removal Kit and Chromogenic
End-point Endotoxin Assay Kit (Chinese Horseshoe
Crab Reagent Manufactory, Xiamen, China). Purified
rTgADF was stored at –80 °C until further use.
The expression and purification of rTgADF were ana-
lyzed using 12 % sodium dodecyl sulfate-polyacrylamide
gel electrophoresis (SDS-PAGE), and rTgADF was trans-
ferred to polyvinylidene difluoride membranes, followed
by blocking in 5 % skim milk for 1 h at 25 °C. After
washing, the membrane was incubated with anti-His pri-
mary antibody (1:1000) or rabbit anti-T. gondii serum
(1:200) at 4 °C overnight. Then, the membranes were
probed with a horseradish peroxidase (HRP)-conjugated
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goat anti-rabbit IgG antibody (1:5000). The blot was vi-
sualized with enhanced chemiluminescence reagents.
Intranasal immunization procedure and sample collection
The mice were randomly divided into 5 groups (8 mice
per group). Four groups were intranasally administered
with 10, 20, 30, or 40 μg of rTgADF that was separately
dissolved in 20 μL of phosphate-buffered saline (PBS).
The control group was immunized with PBS. On days 0,
14, and 21, the nostrils of the mice were slowly instilled
with rTgADF protein solution (10 μL per nostril). Two
weeks after the last immunization, blood was drawn
from the retro-orbital plexus of the mice, centrifuged at
3,000 × g for 10 min, and the serum was isolated. The
nasopharyngeal region, small intestine, and urinary blad-
der of all the mice were exposed and washed according to
a previously described method [20]. Nasal, intestinal, and
vesical washes were centrifuged at 3,000 × g for 10 min,
and collected in Eppendorf tubes. All samples were stored
at –20 °C for evaluation of antibody content.
Determination of antibodies
Enzyme-linked immunosorbent assay (ELISA) was used
to detect the levels of rTgADF-specific antibody, IgG in
the serum, and secretory IgA (sIgA) in the mucosal
washes [21]. A 96-well plate was coated with rTgADF at
a concentration of 5 μg/mL. The serum was diluted
1:300 for IgG, and the mucosal washes were not diluted
for sIgA. HRP-conjugated goat anti-mouse IgG (diluted
1:2500) or IgA (diluted 1:1000) was used as the second-
ary antibody. Absorbance was read at 492 nm by using a
microplate reader (Bio-Tek, VT, USA). The average
value of three independent experiments was recorded
for each sample.
Cytokine assays
The immunized mice were dissected under aseptic con-
ditions. The spleens were harvested, gently ground, and
then passed through stainless-steel meshes in PBS. Sple-
nocyte suspensions were prepared after the removal of
erythrocytes [22]. The cells were seeded in 24-well mi-
crotiter plates at a density of 1.5 × 106 cells per well and
stimulated with rTgADF (10 μg/mL). The plates were in-
cubated in 5 % CO2 at 37 °C. Concentrations of IL-2
and IL-4 at 24 h, IL-10 at 72 h, and IFN-γ at 96 h in the
harvested cell-free supernatants were assayed using
ELISA kits (PeproTech, USA), according to the manu-
facturer’s instructions.
Splenocyte proliferation assay
The isolated splenocytes were plated at 5 × 105 cells per
well in 96-well plates and incubated with a cell-culture
medium, concanavalin A (Con A; 5 μg/mL), and rTgADF
(10 μg/mL). Cell proliferative activity was measured using
the cell counting kit CCK-8 (Dojindo, Japan), according to
the manufacturer’s instructions. Absorbance was measured
at 450 nm. The stimulation index (SI) was calculated as
follows: SI = average OD450 values from stimulated cul-
tures/average OD450 values from non-stimulated cultures.
Parasite challenge
Two groups of BALB/c mice (30 mice per group) were
immunized with PBS or 30 μg of rTgADF, as mentioned
above. Twenty-two mice from each group were orally in-
fected (intragastric administration) with a dose of 4 × 104
tachyzoites for the acute assay. Thereafter, survival times
of the infected mice were recorded daily. The other 8 mice
per group were challenged with 1 × 104 tachyzoites for the
chronic model. Four weeks later, real-time PCR was used
to quantify tachyzoite loads in the liver and brain for de-
tecting the SAG1 gene, as previously described [23].
Statistical analyses
SPSS 11.5 software was used for the statistical analysis.
The results of antibody responses, lymphocyte prolifera-
tion, cytokine assays, and tachyzoite loads were presented
as mean ± SD values for three independent experiments.
The normality test was conducted using the Shapiro–Wilk
test. Comparisons between groups were performed using
one-way analysis of variance (ANOVA). The difference
was considered statistically significant if P < 0.05. The sur-




The full-length ORF sequence of TgADF was amplified
using RT-PCR, and the expected size was 357 bp (Fig. 1a).
TgADF was inserted into pET-30a(+) and verified using
PCR, restriction endonuclease digestion, and sequencing.
After induction with 0.1 mM IPTG at 25 °C, rTgADF was
expressed successfully in E. coli and then purified using
Ni-NTA agarose. SDS-PAGE showed that the isolated
protein was soluble and approximately 20 kDa, which is
the molecular weight of the expressed rTgADF protein
and a polyhistidine tag (Fig. 1b). Western blotting indi-
cated that the purified rTgADF protein was able to com-
bine with the anti-His antibody and rabbit anti-T. gondii
serum (Fig. 1c).
Evaluation of mucosal immune response
We estimated nasal, intestinal, and vesical sIgA as in-
dexes for mucosal immune response. Significantly
higher levels of sIgA titers were observed in the nasal,
intestinal, and vesical washes in mice immunized with
20, 30, or 40 μg of rTgADF than in the control groups
(P < 0.05; Fig. 2). The sIgA levels in three mucosal
washes in the 30- and 40-μg groups were prominently
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higher than that in the 20-μg group. Moreover, an ap-
parent predominance of the 30-μg group over the 40-
μg group was observed on the basis of the vesical
washes. Results of the sIgA antibody levels in the mu-
cosal washes demonstrated that 30 μg of rTgADF elic-
ited the strongest response.
Systemic immune response analysis
Humoral and cellular immune responses were evaluated
by analyzing IgG antibody levels in the serum, splenocyte
proliferation, and cytokine production. High IgG titers
were detected in the serum samples of all immunized
mice (P < 0.05; Fig. 3). The OD values for IgG were
Fig. 2 rTgADF-specific sIgA antibody responses in the mucosal washes. Nasal, intestinal, and vesical washes were harvested from the immunized
(different doses of rTgADF) and control mice (PBS) two weeks after the last immunization. The sIgA antibodies were detected using ELISA. Results
are expressed as mean ± SD (n = 8) for three independent experiments. *, P < 0.05 compared to the PBS group; a, P < 0.05 compared to the 20-μg
group. b, P < 0.05 compared to the 40-μg group
Fig. 1 PCR detection of TgADF and SDS-PAGE and western blotting of rTgADF. a ORF of TgADF was amplified using PCR and examined with 1 %
agarose gel electrophoresis. The length of the ORF was 357 bp. b TgADF was expressed in E. coli, purified using Ni-NTA agarose, detected with
12 % SDS-PAGE, and stained with Coomassie brilliant blue. Lane 1: Purified rTgADF displayed an apparent molecular mass of 20 kDa. c Western
blotting showed that purified rTgADF (lane 2) reacted with anti-His antibody or rabbit anti-T. gondii serum, whereas E. coli containing the empty
plasmid induced by IPTG did not show any band (lane 1)
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continuously increased following an increase in the
immunization dosage, and the 40-μg group showed the
highest titer among all the immunized groups (P < 0.01).
Splenocytes from the 30-μg and 40-μg groups exhibited a
significantly greater proliferative response to rTgADF than
splenocytes from the control group. No statistically signifi-
cant differences were detected in the 10-μg, 20-μg, and
control groups. Meanwhile, splenocytes from all groups
proliferated to comparable levels in response to ConA
(Table 1). In addition, we observed that splenocytes from
all the immunized groups secreted significantly high levels
of IFN-γ and IL-2 when compared with the control group,
and the highest levels were elicited by 30 μg of rTgADF
(Fig. 4a and b). In contrast, IL-4 and IL-10 levels displayed
no significant changes between the immunized and con-
trol groups (P > 0.05; Fig. 4c and d).
Assessment of protection against T. gondii infection
Survival curves of the mice are shown in Fig. 5a. After
the oral challenge with T. gondii, the mice showed symp-
toms such as vertical hair, lassitude, and lethargic and
decreased appetite. Most of the mice in the control
group were dead within 9 days post-infection, with the last
mouse dying on the 23rd day. However, 36.36 % of the
mice immunized with 30 μg of rTgADF remained alive
30 days post-infection. Similarly, rTgADF immunization
protected against chronic infection. The tachyzoite load in
the livers and brains was significantly lower in the immu-
nized mice {13.89 ± 1.27 (105/g) and 6.33 ± 0.43 (105/g),
respectively)} than in the control mice {43.09 ± 3.03 (105/g)
and 12.92 ± 3.30 (105/g), respectively}, which showed a re-
duction in the tachyzoite load by 67.77 % in the liver and
51.01 % in the brain when compared with the control
group (Fig. 5b).
Discussion
In the current study, we investigated the protective cap-
acities of rTgADF as an intranasal vaccine. The nasal
route is easily accessible, requires low doses of an anti-
gen, triggers mucosal immune responses at local and
distant mucosa sites, and elicits systemic immune re-
sponse [24]. Intranasally administered rTgADF was able
to penetrate the nasal epithelium, where it was proc-
essed by the antigen-presenting cells. This process leads
to the activation of T and B cells that develop into IgA
plasma cells [17, 25, 26]. Mature sIgAs are compounded
in the regional lymph nodes, and then enters circulation
via the thoracic duct. They can reach distant mucosal
sites (e.g. intestines, respiratory tract, genital tract, and
salivary glands) [16, 17]. Interestingly, our experiments
showed that rTgADF-specific sIgA levels in the nasal, in-
testinal, and vesical washes were the highest in the 30-
μg group. The specific sIgA antibodies play a key role as
the first line of defense against T. gondii infection [27].
Previous studies have indicated that nasal delivery of
an antigen could also stimulate systemic humoral and
cellular immune responses [28, 29]. Serum IgG has an
important supporting role in systemic humoral immune
function, and it is required for protecting the host cells
against tachyzoite invasion [30]. In this study, all groups
immunized with different doses of rTgADF showed sig-
nificantly higher serum IgG levels than the control
group. Although the 40-μg group showed the highest
IgG titers, the best immune dose was ascertained by a
combination of all the indicators, including splenocyte
proliferation and cytokine and sIgA titers.
We evaluated the cellular immune response in the
mice immunized with rTgADF. Splenocyte proliferation
Fig. 3 rTgADF-specific IgG antibody responses in the serum.
Determination of IgG antibodies in serum samples collected from
the immunized (different doses of rTgADF) and control mice (PBS)
two weeks after the last immunization. Titers were the average of
duplicate readings. Results are mean ± SD values (n = 8) for three
independent experiments; *, P < 0.05 compared to the PBS group;
#, P < 0.01 compared to the other immunized groups
Table 1 Splenocyte proliferative responses in immunized mice
stimulated with rTgADF or ConA
Groupsa Proliferation (Stimulation Index)b
rTgADF ConA
PBS 0.883 ± 0.0135 2.192 ± 0.1491
10 μg rTgADF 0.910 ± 0.0318 2.073 ± 0.1182
20 μg rTgADF 0.952 ± 0.0741 2.231 ± 0.1215
30 μg rTgADF 2.542 ± 0.1213* 2.284 ± 0.1743
40 μg rTgADF 2.391 ± 0.1912* 2.212 ± 0.1811
*P < 0.05 compared to the PBS group
aSplenocytes from mice (n = 8 per group) intranasally immunized with PBS and
different doses of rTgADF were harvested two weeks after the last
immunization and stimulated with rTgADF or ConA
bThe level of splenocyte proliferation is expressed as the stimulation index (SI).
Results represent mean ± SD values of three independent experiments
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showed a 3-fold increase in the 30-μg and 40-μg groups.
Expressions of IFN-γ and IL-2 were obviously increased
in all immunized groups, especially the 30-μg group.
IFN-γ is the major mediator of resistance against T. gon-
dii [31]; it can activate macrophages and NK cells to
engulf the pathogen and directly stimulate CD8+ T cells to
exert cytotoxic effects [31, 32]. IL-2 is secreted by acti-
vated CD4+ Th1 cells, which promote T-cell proliferation,
stimulate IFN-γ production, and enhance cytotoxicity
[33]. Recombinant IL-2 administration enhances survival
against a lethal challenge with T. gondii [34]. However,
differences in IL-4 and IL-10 levels were not obvious be-
tween the control and immunized groups. These results
showed that rTgADF activated Th1-typemediated immun-
ity, which could provide protection against T. gondii
infection.
Fig. 4 Cytokine concentrations of splenocytes from the immunized mice after stimulation with rTgADF. Splenocytes were collected from the
mice two weeks after the last immunization and stimulated with 10 μg/mL of rTgADF. ELISA was used to examine the levels of IFN-γ (a), IL-2 (b),
IL-4 (c), and IL-10 (d). Results are presented as means ± SD (pg/mL) for three independent experiments. *, P < 0.05 compared to the PBS group;
#, P < 0.01 compared to the other immunized groups
Fig. 5 Protection of the mice immunized with rTgADF against oral challenge. The mice were intranasally immunized with PBS or 30 μg of
rTgADF. a Survival curves of the mice (n = 22) challenged with 4 × 104 tachyzoites (acute infection) and observed daily for mortality. b Abundance
of tachyzoites was detected in the liver and brain of the mice (n = 8) after being challenged with 1 × 104 tachyzoites (chronic infection). Results
are expressed as mean ± SD values. *, P < 0.05 compared to the PBS group
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On the basis of the mucosal and systemic immune in-
dictors, the best dose of rTgADF was confirmed to be
30 μg, which was lower than the reported intramuscular
dose (100 μg) [14]. Further, the protective efficacy of in-
tranasal immunization with 30 μg of rTgADF against T.
gondii was investigated. When the mice were orally chal-
lenged with tachyzoites, the survival rate of the immu-
nized group was increased by 36.36 %, which was
superior to that of mice immunized intramuscularly with
the TgADF gene or protein [14, 15]. Compared with
rTgPDI, rTgACT, and rTgMDH reported by our group,
the survival rate attributable to rTgADF was close to
that of rTgPDI but obviously lower than that of rTgACT
and rTgMDH. In this study, the tachyzoite loads in the
tissues were also significantly reduced, which was con-
sistent with the results of the above-mentioned three
proteins.
Conclusions
In this study, our results demonstrated that intranasal
immunization with rTgADF leads to the activation of
both mucosal and systemic immune responses, resulting
in protection against oral challenge with the RH strain
of T. gondii. The immune efficacy may well be improved
by combining rTgADF with other effective antigens such
rTgMDH or adaptive adjuvants.
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